GFAP and Alzheimer disease: Interestingly, 3xTg-AD mice that received um-PEA subcutaneous administration for 3 months, before being tested at 12 months of age, showed restored astrocyte GFAP immunoreactivity to the level of non-Tg controls, also improving their outcome in behavioral assessment of short-term memory [219].